Telomere lengths in PBMC from patients with BMF. Telomere lengths in PBMC were measured by flow cytometric fluorescence in situ hybridization. (A) Telomere length in 234 healthy control subjects between the ages of 1 day and 94 years. The 1st, 5th, 25th, 50th, 75th, 95th, 99th percentiles of healthy controls are shown. (B) Telomere length in 160 patients with BMF from whom telomere measurements were obtained. (C) Telomere length in patients enrolled in the study with the diagnosis of DC. The red squares highlight patients with DC, while gray circles represent the remaining patients with BMF. (D) Telomere lengths in patients with DBA (highlighted in blue). (E) Telomere length in patients with SDS (highlighted in pink). (F) Telomere length in patients with MDS (highlighted in green). Arrows indicate patients in whom a pathogenic C35T TERC gene mutation was identified. (G) Telomere length in patients with PNH (highlighted in brown). (H) Telomere length in patients with aplastic anemia not otherwise classified (AA, highlighted in purple). Arrows indicate patients in whom a pathogenic TERT gene mutation was identified (from left to right; Y846C/H876Q, A716V, A716V). Stippled arrows indicate patients with the variant H412Y. (I) Telomere length in patients with other forms of IBMFS (Pearson syndrome, Fanconi anemia, and FPD, from left to right, highlighted in gold).